<DOC>
	<DOCNO>NCT00516685</DOCNO>
	<brief_summary>The purpose study determine whether recombinant human EGF-rP64K/Montanide ISA 51 vaccine safe , immunogenic effective treatment stage IIIb/IV non-small-cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Non-Small Cell Lung Cancer ( NSCLC ) Stages IIIB/IV</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Patients sign informed consent form . Patients eighteen year age histologically cytologically confirm NSCLC advance stage IIIb IV , amenable attempt curative chemoradiotherapy and/or surgery . Patients measurable lesion , define measurable least one dimension ( refer high diameter ) diameter equal high 20 mm use conventional technique ( PET , CT scan , MRI , Rx ) equal high 10 mm use CT scan . Patients finish last cycle chemotherapy and/or radiotherapy le 4 week prior randomization 8 week . Female patient reproductive potential must negative pregnancy test . Those female volunteer admit study must use reliable mean contraception tubal ligation , oral contraceptive IUD . ECOG status 0 2 . Patients normal organ bone marrow function , define parameter accordance provide normal lab reference range . Patients evidence objective disease progression , 1 month finish first line chemotherapy per RECIST . Patients candidate combined modality treatment . Patients receive immunosuppressive therapy include corticosteroid . Patients receive immunotherapy within previous 3 month . Patients participate clinical study within previous 30 day . Patients may allergic component vaccine . Medical reason consider investigator disqualification study significant uncontrolled comorbid disease potential noncompliance protocol . Patients bear brain metastasis primary lung tumor . Patients bear second primary tumor . Patients show progressive disease finish first line chemotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>LUNG CANCER</keyword>
	<keyword>NSCLC</keyword>
	<keyword>EGF</keyword>
	<keyword>CANCER VACCINE</keyword>
	<keyword>IMMUNOTHERAPY</keyword>
</DOC>